Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Watson Pharmaceuticals has received final approval from the FDA on its abbreviated new drug application for its drug combination of oxycodone hydrochloride and ibuprofen tablets in the 5mg/400mg strength.
Subscribe to our email newsletter
Watson’s oxycodone hydrochloride and ibuprofen product is the generic equivalent to Forest Laboratories’s Combunox, which is indicated for the short-term (not more than seven days) management of acute, moderate to severe pain.
Watson intends to launch its oxycodone hydrochloride and ibuprofen product immediately.